Celltrion Reports the Results for Yuflyma in P-III Trial for the Treatment of Plaque Psoriasis
Shots:
- The P-III interchangeability trial evaluates the safety and efficacy of Yuflyma with its originator drug Humira in patients (n=367) with moderate-to-severe plaque psoriasis
- As per the results, Yuflyma depicted an equivalence between the two arms with similar results in PK, efficacy & safety
- Based on these results, the company plans to apply to receive interchangeability approval from the US FDA to establish Yuflyma as a biosimilar alternative to Humira. Additionally, Celltrion launched Yuflyma in the US in July & received the US FDA’s approval for 2 different doses in Sep 2023
Ref: Korea Biomed | Image: Celltrion
Related News:- Celltrion Launches Yuflyma (biosimilar, adalimumab) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
